SEC Company Response from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Feb 6, 2019
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 6, 2019 · CIK: 0001671502 · Accession: 0001213900-19-001766
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229083
Letter
Cellect Biotechology Ltd.
23 Hata’as Street
Kfar Saba, 44425, Israel
February 6, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: Cellect Biotechnology Ltd. (CIK: 0001671502)
Registration Statement No. 333-229083
on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Cellect Biotechnology Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on Thursday, February 7, 2019, at 5:00 PM, Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
Cellect
Biotechnology Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Cellect Biotechology Ltd.
23 Hata’as Street
Kfar Saba, 44425, Israel
February 6, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Cellect Biotechnology Ltd. (CIK: 0001671502)
Registration Statement No. 333-229083
on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Cellect Biotechnology Ltd.
(the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement
pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become
effective on Thursday, February 7, 2019, at 5:00 PM, Eastern Time, or as soon thereafter as is practicable.
The Registrant understands
that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation
of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public
offering of the securities specified in the Registration Statement.
Very truly yours,
Cellect
Biotechnology Ltd.
By:
/s/ Shai Yarkoni
Shai Yarkoni, Chief Executive Officer